Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A for Lower Urinary Tract Symptoms Due to BPH
NCT01107392Phase 2Completed
- Sponsor
- Allergan
- Start
- Aug 2010
- Primary completion
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Botox with Placebo (2 arms). Primary endpoint: International Prostate Symptom Score at 12 weeks. Started Aug 2010; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01107392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01107392.